Akari Therapeutics Plc (AKTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 24 WEST 40TH STREET
NEW YORK, NY 10018
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2016
MRQ
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 68,9206,216
Cash and cash equivalents 68,9206,216
Restricted cash and investments  142
Receivables 10 
Other undisclosed current assets 72873
Total current assets: 69,6586,431
Noncurrent Assets
Property, plant and equipment 4149
Intangible assets, net (including goodwill) 52 
Intangible assets, net (excluding goodwill) 52 
Restricted cash and investments 142 
Total noncurrent assets: 23549
TOTAL ASSETS: 69,8946,480
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 4,7291,715
Employee-related liabilities  4
Accounts payable 4,3211,359
Accrued liabilities 408352
Due to related parties  118
Other undisclosed current liabilities 16,396(474)
Total current liabilities: 21,1251,359
Noncurrent Liabilities
Liabilities, other than long-term debt  33
Other liabilities  33
Other undisclosed noncurrent liabilities 49235
Total noncurrent liabilities: 49268
Total liabilities: 21,1741,627
Equity
Equity, attributable to parent 48,7204,853
Common stock 18,341927
Additional paid in capital 87,01934,116
Accumulated other comprehensive income 156 
Accumulated deficit (56,797)(30,190)
Total equity: 48,7204,853
TOTAL LIABILITIES AND EQUITY: 69,8946,480

Income Statement (P&L) ($ in thousands)

3/31/2016
TTM
12/31/2015
12/31/2014
Revenues
(Financial Services Revenue)
  549
Cost of revenue
(Financial Services Costs)
 (22,973) 
Gross profit: (22,973)549
Operating expenses (30,585)(10,177)
Other undisclosed operating income (loss) 22,973(549)
Operating loss: (30,585)(10,177)
Nonoperating income (expense) (14,733)529
Other nonoperating income  529
Interest and debt expense (3,054) 
Loss from continuing operations before equity method investments, income taxes: (48,371)(9,648)
Other undisclosed income from continuing operations before income taxes 3,054 
Loss from continuing operations: (45,318)(9,648)
Loss before gain (loss) on sale of properties: (45,318)(9,648)
Net loss available to common stockholders, diluted: (45,318)(9,648)

Comprehensive Income ($ in thousands)

3/31/2016
TTM
12/31/2015
12/31/2014
Net loss: (45,318)(9,648)
Comprehensive loss: (45,318)(9,648)
Other undisclosed comprehensive income, net of tax, attributable to parent 110 
Comprehensive loss, net of tax, attributable to parent: (45,207)(9,648)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: